This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Under scenario 1, severity levels were assumed to remain constant. Under scenario 2, optimal coverage was arbitrarily defined as 100% for schizophrenia, 70% for anxiety and affective disorders and for harmful use of alcohol, and 30% for alcohol dependence (the average coverage for all mental disorders was 67%). Severity levels were kept constant for those currently under treatment, but were varied for the "extra cases" in treatment under optimal coverage, to reflect the severity one would expect if those not currently in contact with services were covered. Under scenario 3, 100% coverage was assumed, keeping optimal treatment strategies constant and defining severity on the basis of that observed among all cases in current treatment. The time horizon was one year.
Outcomes assessed in the review
The outcomes assessed were: the prevalence of schizophrenia, anxiety, affective and alcohol use disorders in Australia; the percentage of current coverage and effective current coverage related to each disorder; and the burden of disease observed in the population under study.
The true burden of each disorder, defined as the burden in the absence of treatment, was then calculated by adding the burden observed plus the burden averted by current treatment and coverage. Most of the results presented in the paper were a summary of findings already published in parental studies. Further details can be found elsewhere (see Other Publications of Related Interest).
Study designs and other criteria for inclusion in the review
All data were based on Australian national mental health surveys.
Sources searched to identify primary studies
Not stated.
Criteria used to ensure the validity of primary studies
Methods used to judge relevance and validity, and for extracting data
Number of primary studies included
Two primary studies (national surveys) were included in the review.
Methods of combining primary studies
The results of the primary studies were not combined.
Investigation of differences between primary studies
Not applicable, as the data were based on two national mental health surveys, each collecting data on different mental health disorders. 78, 209; bipolar disorder 71, 308; panic disorder/agoraphobia 175, 994; social phobia 206, 976; GAD 376, 290; PTSD 327, 071 ; harmful use of alcohol 251,911; alcohol dependence 227,431; and schizophrenia 39,048. The total number of patients suffering from any of these mental disorders was 2,402,613.
The total burden associated with each mental disorder, expressed in number of years lived with disability (YLDs), was: depression 143,018; dysthymia 37,781; bipolar disorder 13,363; panic disorder/agoraphobia 25,338; social phobia 30,058; GAD 85,341; PTSD 60,810; harmful use of alcohol 5,304; alcohol dependence 43,439; and schizophrenia 28,671. The overall burden of mental disorders in the population was 473,123 YLDs.
The coverage (% effective coverage) for each of the mental disorders was: depression 60.2% (31.7%); dysthymia 50.9% (33.3%); bipolar disorder 66.1% (46.2%); panic disorder/agoraphobia 39.1% (23.8%); social phobia 20.8% (6.7%); GAD 37.6% (20.5%); PTSD 39.5% (25.1%); harmful use of alcohol 8.1% (3.6%); alcohol dependence 13.6% (7.8%); and schizophrenia 100% (100%). The overall coverage was 39.5%, of which 22.8% was deemed effective.
Measure of benefits used in the economic analysis
The benefits were expressed as the YLDs averted by current or optimal treatment. They were estimated using data from the Australian national mental health surveys. The YLDs observed were calculated as the prevalence of the only or principal complaint, weighted by the disability weighting associated with that disorder. The YLDs were adjusted for time spent symptomatic using the ratio between current and 12-month cases. The YLDs averted because of treatment were estimated from prevalent cases having received effective treatment. It was assumed that the degree of change in symptoms resulting from effective treatment (measured in effect size units) reflected the degree of change in disability weightings used in the YLD calculations. Health state preference values were adopted from a published study that reported values provided by general practitioners for vignettes of people with each mental health disorder. The total YLDs due to mental disorders in the absence of any treatment were the sum of YLDs observed plus YLDs averted because of treatment.
Direct costs
The direct costs consisted of all health service costs associated with service use and treatment for the patients' only or principal complaint, for the 10 mental disorders examined in the analysis. No further analysis of the costs was provided. The costs and the quantities were not reported separately. Resources used under current treatment were based on patient self-reports, derived from Australian national mental health surveys conducted between 2000 and 2002. Resources used under optimal treatment were based on literature published between 1998 and 2003. The unit costs for both public and private sector were derived from published sources. The total costs for optimal treatment were derived using modelling. All the costs were estimated for 1-year time horizon, therefore discounting was not necessary and was not carried out. All the costs were converted to 1997 prices. It is likely that further details of the costs are provided in the parent studies (see Other Publications of Related Interest).
Statistical analysis of costs
The costs were presented deterministically. However, it was reported that a sensitivity analysis provided confidence intervals (CIs) around the total cost of treatment. The results of the sensitivity analysis were not reported.
CIs around the costs, benefits and cost-effectiveness ratios were calculated. Univariate analyses assessed the impact of changing various investigator-modelled parameters on the cost-effectiveness estimates. In addition, multivariate stepwise linear regressions were conducted for each mental disorder examined, to identify the important contributors to variance around the cost-effectiveness ratios.
Estimated benefits used in the economic analysis
The YLDs averted by current coverage/current treatment (% total YLDs due to mental disorders that were averted by treatment) were: depression 22,559 (16%); dysthymia 4,982 (13%); bipolar disorder 2,536 (19%); overall, all affective disorders 30,078 (15%); panic disorder/agoraphobia 2,375 (9%); social phobia 2,530 (8%); GAD 14,469 (17%); PTSD 6,687 (11%); overall, all anxiety disorders 26,059 (13%); harmful use of alcohol 95 (2%); alcohol dependence 650 (2%); overall, all alcohol use disorders 745 (2%); schizophrenia 3,774 (13%). The overall YLDs averted by current coverage/current treatment were 60,655 (13%).
The YLDs averted by current coverage/optimal treatment were: depression 32,583 (23%); dysthymia 7,446 (20%); bipolar disorder 4,529 (34%); overall, all affective disorders 44,557 (23%); panic disorder/agoraphobia 3,304 (13%); social phobia 3,885 (13%); GAD 23,424 (27%); PTSD 9,489 (16%); overall, all anxiety disorders 40,101 (20%); harmful use of alcohol 191 (4%); alcohol dependence 2,061 (5%); overall, all alcohol use disorders 2,253 (5%); schizophrenia 6,217 (22%). The overall YLDs averted by current coverage/optimal treatment were 93,128 (20%).
The YLDs averted by optimal coverage/optimal treatment were: depression 37,518 (26%); dysthymia 10,032 (27%); bipolar disorder 4,626 (35%); overall, all affective disorders 52,176 (27%); panic disorder/agoraphobia 5,244 (21%); social phobia 10,201 (34%); GAD 40,981 (48%); PTSD 14,358 (24%); overall, all anxiety disorders 70,784 (35%); harmful use of alcohol 1,059 (20%); alcohol dependence 4,537 (10%); overall, all alcohol use disorders 5,597 (11%); schizophrenia 6,217 (22%). The overall YLDs averted by optimal coverage/optimal treatment were 134,774 (28%).
The YLDs averted by 100% coverage/ optimal treatment were: depression 48,239 (34%); dysthymia 14,105 (37%); bipolar disorder 5,372 (40%); overall, all affective disorders 67,715 (35%); panic disorder/agoraphobia 7,090 (28%); social phobia 14,798 (49%); GAD 57,213 (67%); PTSD 19,289 (32%); overall, all anxiety disorders 98,390 (49%); harmful use of alcohol 1,479 (28%); alcohol dependence 15,124 (35%); overall, all alcohol use disorders 16,603 (34%); schizophrenia 6,217 (22%). The overall YLDs averted by 100% coverage/optimal treatment were 188,926 (40%). The benefits were estimated for a time horizon of one year.
Cost results
The total costs (Aus$ million) associated with current coverage/current treatment were: depression Aus$483.7; dysthymia Aus$70.8; bipolar disorder Aus$60.9; all affective disorders Aus$615.5; panic disorder/agoraphobia Aus$81.7; social phobia Aus$43.6; GAD Aus$112.3; PTSD Aus$158.2; all anxiety disorders Aus$395.7; harmful use of alcohol Aus$9.2; alcohol dependence Aus$63.7; all alcohol use disorders Aus$72.9; schizophrenia Aus$739.9.
The overall costs associated with current coverage/current treatment were Aus$1,824.0 million.
The total costs (Aus$ million) associated with current coverage/optimal treatment were: depression Aus$341.3; dysthymia Aus$28.7; bipolar disorder Aus$108.4; all affective disorders Aus$478.4; panic disorder/agoraphobia Aus$65.4; social phobia Aus$33.1; GAD Aus$118.2; PTSD Aus$149.2; all anxiety disorders Aus$366.1; harmful use of alcohol Aus$1.7; alcohol dependence Aus$118.6; all alcohol use disorders Aus$120.3; schizophrenia Aus$668.2.
The overall costs associated with current coverage/optimal treatment were Aus$1,633.1 million.
The total costs (Aus$ million) associated with optimal coverage/optimal treatment were: depression Aus$375.5; dysthymia Aus$35.3; bipolar disorder Aus$114.8; all affective disorders Aus$525.7; panic disorder/agoraphobia Aus$112.8; social phobia Aus$110.7; GAD Aus$205.1; PTSD Aus$242.2; all anxiety disorders Aus$670.8; harmful use of alcohol Aus$14.6; alcohol dependence Aus$243.2; all alcohol use disorders Aus$257.8; schizophrenia Aus$668.2.
The overall costs associated with optimal coverage/optimal treatment were Aus$2,122.5 million.
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The total costs associated with 100% coverage/optimal treatment were not calculated.
Synthesis of costs and benefits
The costs and benefits were combined in the form of cost-effectiveness ratios. These expressed the cost per YLD averted by current or optimal treatment compared with no treatment.
The total cost/YLD averted by current coverage/current treatment was: No cost-effectiveness ratios were calculated for 100% coverage/optimal treatment.
The results of the univariate sensitivity analyses and regression analyses were not provided. However, they have been reported in the parental specific-disorder studies (see Other Publications of Related Interest).
disorders at a national level.
Validity of estimate of measure of benefit
The estimation of benefits was modelled. The model used was appropriate for this purpose, as it allowed the burden averted by treatment to be evaluated for a variety of assumptions about clinical effectiveness and treatment coverage. The authors considered measures of benefit (i.e. YLD) that appear to have been relevant for the treatments evaluated. They also noted that the disability-adjusted life-years lost could not be assessed since the treatment intervention studies did not use death as an outcome.
Validity of estimate of costs
The perspective of the study was that of the health service (public and private providers). It was likely that all categories of cost were included in the analysis, although the authors did not provide any cost details. Further information was probably provided in the parent studies (see Other Publications of Related Interest). Although the resources used were identified, the quantities were not reported, and neither were the unit costs. This may hinder the generalisability of the authors' results in other settings. One additional limitation of this approach was that the cost data were based on selfreported treatments. A sensitivity analysis was undertaken, but the results were not given. Discounting was not undertaken, which was appropriate as the costs were incurred during a time horizon of one year. The date to which the costs referred was reported, and this improves the reproducibility of the results.
